Morphine Concentrations in Human Urine Following Poppy Seed Paste Consumption

Özbunar, Emine; Aydoğdu, Melike; Döğer, Rukiye; Bostancı, Halil İbrahim; Koruyucu, Meryem; Akgür, Serap Annette

doi:10.1016/j.forsciint.2018.11.026

Cited by 27 publications

(21 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…False‐negative screening results can occur if too much time has passed between opioid use and testing or if metabolites are not present in sufficient quantity to be detectible . A number of substances have also been associated with false‐positive immunoassay results for opioid use, including ingested poppy seeds, as well as dextromethorphan, diphenhydramine, quinine, quinolones, levofloxacin (Levaquin), ofloxacin (Ocuflox) rifampin (Rifadin), and verapamil (Calan) . A 2017 study that compared meconium drug screening with maternal urine drug screening to detect opioid exposure among woman‐newborn dyads at birth found that maternal urine drug screen had a higher sensitivity (0.52; 95% CI, 0.39‐0.65) and specificity (0.88; 95% CI, 0.79‐0.97) for the detection of intrauterine opiate exposure compared with meconium drug screening .…”

Section: Clinical Care During Pregnancy For Women With Oudmentioning

confidence: 99%

Maternity Care for Pregnant Women with Opioid Use Disorder: A Review

Rizk

Simonsen

Roberts

et al. 2019

J Midwife Womens Health

View full text Add to dashboard Cite

Opioid misuse is a problem that is complex and widespread. Opioid misuse rates are rising across all US demographics, including among pregnant women. The opioid epidemic brings a unique set of challenges for maternity health care providers, ranging from ethical considerations to the complex health needs and risks for both woman and fetus. This article addresses care for pregnant women during the antepartum, intrapartum, and postpartum periods through the lens of the opioid epidemic, including screening and counseling, an interprofessional approach to prenatal care, legal considerations, and considerations for care during labor and birth and postpartum. Providers can be trained to identify at-risk women through the evidence-based process of Screening, Brief Intervention, and Referral to Treatment (SBIRT) and connect them with the appropriate care to optimize outcomes. Women at moderate risk of opioid use disorder can be engaged in a brief conversation with their provider to discuss risks and enhance motivation for healthy behaviors. Women with risky opioid use can be given a warm referral to pharmacologic treatment programs, ideally comprehensive prenatal treatment programs where available (a warm referral is a term used when a provider, with the patient's permission, contacts another provider or another service him or herself rather than providing a phone number and referral number). Evidence regarding care for the pregnant woman with opioid use disorder and practical clinical recommendations are provided.

show abstract

Section: Clinical Care During Pregnancy For Women With Oudmentioning

confidence: 99%

Maternity Care for Pregnant Women with Opioid Use Disorder: A Review

Rizk

Simonsen

Roberts

et al. 2019

J Midwife Womens Health

View full text Add to dashboard Cite

show abstract

“…Many opioids can be missed during routine screening, generating significant false-negatives, and it has been reported that screening is also prone to many false-positive results in the presence of poppy seeds and quinolone antibiotics [13,94]. Indeed, poppy seed paste used in foods could lead to positive urine tests for opioids, even if increased cut-off levels are used and different biomarkers are considered for the differential diagnosis, such as the presence of thebaine to ensure justice for each individual [13,95]. Moreover, if an individual is currently taking a lawful medication containing codeine, the test can suggest that he/she has used heroin.…”

Section: Interpretation Of Other Psychoactive Substances Resultsmentioning

confidence: 99%

Abuse of Licit and Illicit Psychoactive Substances in the Workplace: Medical, Toxicological, and Forensic Aspects

Dinis-Oliveira

Magalhães

2020

JCM

View full text Add to dashboard Cite

About one-third of adult life is spent in the workplace. The use of psychoactive substances is a major preventable cause of morbidity and mortality. The consumption of psychoactive substances during or outside working hours greatly increases the frequency and severity of labor accidents, as well as the workers’ poor general state of health and productivity, implying higher costs for enterprises. It is the responsibility of organizations to ensure the safety and health of their workers. These cannot be limited to traditional routine clinical exams, as other aspects also have an impact on health. Thus, prevention and intervention in the consumption of psychoactive substances (e.g., ethanol, opioids, central nervous system stimulants or depressants, hallucinogens, Cannabis derivatives, dissociative substances, and inhalants) in labor activity should be considered as an investment of organizations and not as a cost, in view of the professional, personal, and family advantages for workers and employers, with a potential impact on productivity, security, health, and quality of life at work. Despite the extensive literature on the subject, each article generally focuses on one or another aspect of a very specific nature, not tackling the problem in a holistic way by confronting clinical, safety, and legal issues. This article presents a reflection on the legal, laboratorial, clinical, ethical, forensic, and safety concerns related to the consumption of psychoactive substances in the workplace, and can be a cross-cutting contribution to occupational medicine, forensic medicine, and insurance medicine, as well as for entrepreneurs, lawyers, judges, workers, and technicians from the public and private sectors that develop projects in this area. This discussion is based on general principles established internationally and highlights the role of the occupational healthcare system and other decision-making actors in the prevention and supervision of workplace psychoactive consumption.

show abstract

“…O século XIX foi marcado por grandes avanços medicinais, pois em 1803 o farmacêutico Friedrich Wilhelm Adam Sertürner conseguiu isolar a morfina da espécie Papaver somniferum. Tal acontecimento foi um marco crucial para o início do processo de isolamento de princípios ativos de espécies vegetais, pois pouco tempo depois no ano de 1819 ocorreram as extrações da quinina e quinidina obtidas da espécie Cinchona spp e, posteriormente a atropina da espécie Atropa belladona em 1831 (PUNDARIKAKSHUDU et al, 2018;OZBUNAR et al, 2019).…”

Section: Extração Do óLeo-resinaunclassified

Atividade Terapêutica Da Camellia Sinensis (Chá Verde) Como Auxiliar No Tratamento Da Obesidade: Uma Revisão De Literatura

Bezerra¹,

Guedes²

2020

Farmácia E Promoção Da Saúde

View full text Add to dashboard Cite

Todo o conteúdo deste livro está licenciado sob uma Licença de Atribuição Creative Commons. Atribuição 4.0 Internacional (CC BY 4.0). O conteúdo dos artigos e seus dados em sua forma, correção e confiabilidade são de responsabilidade exclusiva dos autores. Permitido o download da obra e o compartilhamento desde que sejam atribuídos créditos aos autores, mas sem a possibilidade de alterá-la de nenhuma forma ou utilizá-la para fins comerciais.

show abstract

Morphine Concentrations in Human Urine Following Poppy Seed Paste Consumption

Cited by 27 publications

References 17 publications

Maternity Care for Pregnant Women with Opioid Use Disorder: A Review

Maternity Care for Pregnant Women with Opioid Use Disorder: A Review

Abuse of Licit and Illicit Psychoactive Substances in the Workplace: Medical, Toxicological, and Forensic Aspects

Atividade Terapêutica Da Camellia Sinensis (Chá Verde) Como Auxiliar No Tratamento Da Obesidade: Uma Revisão De Literatura

Contact Info

Product

Resources

About